Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genomma Lab InternacionalB de CVMEX:LABB -0.81%66 Days Sales Outstanding is 106.16 as of Mar. 2026, which is 15% above its 10-year median of 92.65. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.70 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 949 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks worse than 76.4% on this metric.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's Days Sales Outstanding or its related term are showing as below:
MEX:LABB'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 79.97 Med: 92.65 Max: 125.37
Current: 106.96
During the past 13 years, Genomma Lab InternacionalB de CV's highest Days Sales Outstanding was 125.37. The lowest was 79.97. And the median was 92.65.
MEX:LABB's Days Sales Outstanding is ranked worse than 76.4% of 949
companies
in the Drug Manufacturers industry
Industry Median: 72
vs MEX:LABB: 106.96
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Days Sales Outstanding Chart
MEX:LABB vs ZTS, UTHR, VTRS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Days Sales Outstanding falls into.
Genomma Lab InternacionalB de CV Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 106.16 mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a Days Sales Outstanding of 106.16 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is 15% above median its historical median of 92.65. Over the past decade, Genomma Lab InternacionalB de CV's Days Sales Outstanding has ranged from 79.97 to 125.37. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #725 out of 949 companies in the Drug Manufacturers industry, placing it in the top 76.4%.
Is Genomma Lab InternacionalB de CV's Days Sales Outstanding too high?
Genomma Lab InternacionalB de CV's current Days Sales Outstanding of 106.16 is 15% above median its 10-year median of 92.65. Over the past 10 years, this metric has ranged from a low of 79.97 to a high of 125.37. The Drug Manufacturers industry median Days Sales Outstanding is 72.00. Genomma Lab InternacionalB de CV's value of 106.16 is 47.4% above this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #725 out of 949 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Days Sales Outstanding compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #725 out of 949 companies for Days Sales Outstanding. This places Genomma Lab InternacionalB de CV in the lower half of its industry. The industry median Days Sales Outstanding is 72.00. Genomma Lab InternacionalB de CV's value of 106.16 is 47.4% above this benchmark. Historically, Genomma Lab InternacionalB de CV's own Days Sales Outstanding has ranged from 79.97 to 125.37 over the past decade. While the company's 10-year median is 92.65 vs. the industry median of 72.00, Genomma Lab InternacionalB de CV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 72.00, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current Days Sales Outstanding of 106.16 is 47.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 72.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Days Sales Outstanding is 106.16, which is 15% above median its own 10-year median of 92.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.70, compared to a current price of MXN14.73 — trading 16.8% below its estimated fair value. The current Days Sales Outstanding is 106.16, which is 15% above median its 10-year median of 92.65 and 47.4% above the Drug Manufacturers industry median of 72.00. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Days Sales Outstanding is 106.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN14.73 is trading 16.8% below its estimated GF Value™ of MXN17.70.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Days Sales Outstanding: 106.16 (15% above median its 10-year median of 92.65)
GF Value™: MXN17.70 vs. price of MXN14.73 (16.8% below fair value)
Industry Position: 47.4% above the Drug Manufacturers median (#725 of 949)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
